



Technology Description

Controlling outbreaks in poultry is the first line of defence against Avian Influenza pandemics in humans. This involves measures such as increased biosecurity, quarantine, surveillance and vaccination. To enable improved surveillance of poultry flocks, DIVA Solutions Pty Ltd. has developed a highly specific biomarker for incorporation into avian vaccine preparations. The proprietary biomarker is highly specific and sensitive, and circumvents the many shortcomings of conventional surveillance technologies for Avian Influenza in poultry.

Value Proposition and Competitive Advantages

The DIVA Solutions DIVA strategy demonstrates several advantages over existing DIVA surveillance strategies for Avian Influenza:

- Multiple Subtype Compatibility- Our technologies allow for the surveillance of multiple subtypes of the virus
- Highly accurate and Inexpensive testing- An ELISA has been developed by DIVA Solutions and is inexpensive, rapid and simple to perform
- Low Cost Manufacturing Compatibility- Our biomarker is readily available to the animal vaccine manufacturing industry and is cost-effective due to the small amount required.

Current Status/ Next Steps

DIVA Solutions is seeking to license its technology to one or more manufacturers of poultry avian influenza vaccines.

Contact Details

Mr Russell Barnett, CEO DIVA Solutions Pty Ltd
Russell@ventureconsultants.com.au
+61 (8) 9320 5138